Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RNXT

RenovoRx Inc

0.9301

Jul 10 • 04:00PM ET -0.0097 (-1.03%)

Healthcare Biotechnology USA Nano NASD

Peers: ATOS NTRB OTLK XLO GLSI PALI PRLD RZLT TARA TLPH

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	41.90M
Enterprise Value	29.73M
Income	-12.27M
Sales	1.49M
Book/sh	0.25
Cash/sh	0.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Aug 26, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	28.12
P/B	3.72
P/C	3.39
P/FCF	-
EV/EBITDA	-
EV/Sales	19.96
Quick Ratio	6.95
Current Ratio	7.15
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-0.33
EPS next Y	-0.14
EPS next Q	-0.07
EPS this Y	7.81%
EPS next Y	50.85%
EPS next 5Y	-
EPS past 3/5Y	33.86% 6.34%
Sales past 3/5Y	- -
EPS Y/Y TTM	16.12%
Sales Y/Y TTM	520.42%
EPS Q/Q	-20.10%
Sales Q/Q	185.79%
Earnings	May 14 AMC
EPS/Sales Surpr.	-12.50% 19.91%

Insider Own	3.49%
Insider Trans	2.28%
Inst Own	19.01%
Inst Trans	2.91%
ROA	-81.85%
ROE	-100.47%
ROIC	-108.16%
Gross Margin	78.71%
Oper. Margin	-864.27%
Profit Margin	-823.98%
SMA20	1.08%
SMA50	3.93%
SMA200	-3.73%
Trades

Shs Outstand	45.05M
Shs Float	43.48M
Short Float	0.80%
Short Ratio	1.20
Short Interest	0.35M
52W High	1.45 -35.86%
52W Low	0.70 32.76%
Volatility	4.50% 5.19%
ATR (14)	0.05
RSI (14)	51.61
Beta	0.99
Rel Volume	0.14
Avg Volume	289.31K
Volume	40,077

Perf Week	1.09%
Perf Month	8.15%
Perf Quarter	-4.94%
Perf Half Y	-7.91%
Perf YTD	10.71%
Perf Year	-30.59%
Perf 3Y	-53.73%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	7.00
Prev Close	0.94
Price	0.93
Change	-1.03%

Jun-11-26 08:30AM	RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP in Locally Advanced Pancreatic Cancer (GlobeNewswire)
Jun-04-26 08:30AM	RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd (GlobeNewswire) +7.71%
May-28-26 08:30AM	RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer (GlobeNewswire) +6.20%
May-26-26 08:30AM	RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting (GlobeNewswire)
May-19-26 08:30AM	RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th (GlobeNewswire)
08:30AM	Loading…
May-15-26 08:30AM	RenovoRx, Inc. Q1 2026 Earnings Call Summary (Moby)
01:01AM	RenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Expansion (GuruFocus.com)
May-14-26 04:05PM	RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter (GlobeNewswire)
May-13-26 09:20AM	RenovoRx Inc (RNXT) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-29-26 08:30AM	RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET (GlobeNewswire)
Apr-23-26 08:30AM	RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting (GlobeNewswire) -5.09%
Apr-14-26 08:30AM	Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting (GlobeNewswire)
Apr-08-26 08:30AM	RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum (GlobeNewswire)
Apr-01-26 02:20PM	RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 (GlobeNewswire)
Mar-30-26 11:01PM	RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -5.31% -5.61%
04:05PM	Loading…
04:05PM	RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-27-26 09:19AM	Earnings To Watch: RenovoRx Inc (RNXT) Reports Q1 2026 Result (GuruFocus.com)
Mar-26-26 08:30AM	RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment (GlobeNewswire) +5.45%
Mar-23-26 08:30AM	RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement (GlobeNewswire) +11.00%
Mar-20-26 08:30AM	RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET (GlobeNewswire)
Mar-18-26 08:35AM	RenovoRx Announces $10 Million at Market Private Placement (GlobeNewswire) +6.59%
Mar-03-26 05:35PM	Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.51%
Feb-28-26 09:01AM	RenovoRx advances RenovoCath adoption at U.S. cancer centers (TipRanks)
Feb-27-26 08:30AM	RenovoRx Advancing RenovoCath Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum (GlobeNewswire)
Feb-26-26 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting (GlobeNewswire)
Feb-10-26 08:30AM	RenovoRx Establishes RenovoCath Medical Advisory Board (GlobeNewswire)
Feb-05-26 08:30AM	RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer (GlobeNewswire)
Feb-04-26 08:30AM	RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting (GlobeNewswire)
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire) +8.33%
Jan-28-26 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting (GlobeNewswire)
08:30AM	Loading…
Jan-20-26 08:30AM	RenovoRx Expands RenovoCath Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center (GlobeNewswire)
Jan-14-26 08:30AM	RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 (GlobeNewswire)
Jan-08-26 08:30AM	RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 (GlobeNewswire) +13.86%
Dec-11-25 08:30AM	RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 (GlobeNewswire)
Dec-08-25 09:00AM	Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025 (ACCESSWIRE)
Dec-01-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th (GlobeNewswire) -6.59%
Nov-19-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th (GlobeNewswire) -6.38%
Nov-14-25 12:04AM	RenovoRx Inc (RNXT) Q3 2025 Earnings Call Highlights: Strong Commercial Momentum and Strategic ... (GuruFocus.com) -23.03%
Nov-13-25 05:30PM	RenovoRx, Inc. (RNXT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update (GlobeNewswire)
Nov-12-25 07:36AM	RenovoRx Inc (RNXT) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com) -6.54%
Nov-06-25 08:30AM	RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD (GlobeNewswire) -6.23%
Nov-04-25 08:30AM	RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th (GlobeNewswire) -6.42%
Oct-27-25 08:30AM	RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET (GlobeNewswire)
Oct-17-25 09:50AM	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation (PR Newswire)
Oct-09-25 08:30AM	RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baere, MD, PhD (GlobeNewswire) -7.44%
Sep-25-25 08:30AM	RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites (GlobeNewswire)
Sep-11-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th (GlobeNewswire) +5.98%
Aug-20-25 08:30AM	RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025 (Business Wire) -5.58%
Aug-15-25 03:24AM	RenovoRx Inc (RNXT) Q2 2025 Earnings Call Highlights: Strong Market Demand and Strategic Trials ... (GuruFocus.com) -22.94%
Aug-14-25 05:20PM	RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review (Business Wire)
Aug-06-25 08:30AM	RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath Device with Growing Customer Demand and Key Leadership Hire (GlobeNewswire)
Jul-28-25 08:30AM	RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath Device to Solid Tumors (Business Wire)
Jul-14-25 08:30AM	RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET (Business Wire) +8.95%
Jun-05-25 11:00PM	RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results (Insider Monkey)
May-16-25 09:42AM	Q1 2025 RenovoRx Inc Earnings Call (Thomson Reuters StreetEvents) +6.31%
03:15AM	RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ... (GuruFocus.com)
May-15-25 07:30PM	RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.71%
04:05PM	RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-14-25 08:30AM	RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st (Business Wire)
May-06-25 08:30AM	U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP) Therapy Platform (Business Wire)
May-01-25 08:30AM	RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET (Business Wire)
Apr-29-25 08:30AM	Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRxs Ongoing Phase III TIGeR-PaC Clinical Trial (Business Wire)
Apr-16-25 08:30AM	RenovoRx Increases U.S. Production of RenovoCath Devices to Meet Growing Demand from Oncology Community (Business Wire) +14.44%
Apr-04-25 08:30AM	RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th (Business Wire)
Apr-01-25 08:30AM	RenovoRx Reports Initial Revenues from RenovoCath Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (Business Wire)
Mar-28-25 08:00AM	RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting (Business Wire)
Mar-26-25 08:00AM	RenovoRx Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting (Business Wire)
Mar-20-25 08:00AM	RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET (Business Wire)
Mar-19-25 08:00AM	RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025 (Business Wire)
Feb-26-25 08:00AM	RenovoRx Advances Commercialization of RenovoCath with Several New Purchase Orders, Including Customer Reorders (Business Wire)
Feb-13-25 08:00AM	RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery (Business Wire) -11.21%
Feb-11-25 07:00AM	RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock (Business Wire)
Feb-07-25 03:11AM	RenovoRx Prices $12.1 Million Public Offering; Shares Decline Post-Announcement (GuruFocus.com) -20.55%
Feb-06-25 08:49PM	RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock (Business Wire)
04:05PM	RenovoRx Announces Proposed Public Offering (Business Wire)
Jan-27-25 12:48PM	ASCO GI: RenovoRXs TAMP system reduces side effects in pancreatic cancer (Clinical Trials Arena)
08:00AM	RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025 (Business Wire)
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-08-25 08:00AM	RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025 (Business Wire)
Dec-30-24 08:00AM	RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform (Business Wire) +6.92%
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire)
Dec-11-24 08:00AM	RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer (GlobeNewswire)
Dec-10-24 08:00AM	RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET (GlobeNewswire)
Dec-06-24 05:01AM	RenovoRx begins commercialisation of RenovoCath device (Medical Device Network)
Dec-05-24 08:00AM	RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath Delivery System (GlobeNewswire) +15.97%
Nov-20-24 08:45AM	Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire) +7.21%
Nov-14-24 08:00AM	RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Sep-25-24 08:30AM	RenovoRx Increases Production of FDA-Cleared RenovoCath Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians (GlobeNewswire)
Sep-19-24 08:30AM	RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP for Targeted Treatment of Locally Advanced Pancreatic Cancer (GlobeNewswire)
Aug-27-24 08:30AM	RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York (GlobeNewswire)
Aug-14-24 12:13PM	RenovoRx continues drug-device combo Phase III trial in pancreatic cancer (Medical Device Network)
08:30AM	RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire)
Aug-13-24 10:52PM	RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024 (InvestorPlace)
Jul-31-24 08:30AM	RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist (GlobeNewswire) -6.98%
Jul-08-24 08:30AM	RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist (GlobeNewswire) +6.61%
Jun-26-24 08:30AM	University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial (GlobeNewswire)
Jun-10-24 08:30AM	RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships (GlobeNewswire)
May-30-24 08:30AM	RenovoRx CEO Issues Update Letter to Shareholders (Business Wire)

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in 2009 and is headquartered in Mountain View, CA.

FounderDr. Ramtin Agah M.D.

CEOMr. Shaun R. Bagai

CGMAMr. Ronald B. Kocak CPA

CFO & Principal Accounting OfficerMr. Mark Voll

Vice President of Operations and R&DMr. Robert Strasser

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VOLL MARK	Chief Financial Officer	May 19 '26	Buy	0.79	25,000	19,690	142,380	May 21 07:00 AM
Agah Ramtin	Chief Medical Officer	Jan 21 '26	Buy	1.00	10,000	9,975	798,460	Jan 22 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 31 '25	Buy	0.86	9,795	8,424	788,460	Jan 05 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 30 '25	Buy	0.83	205	169	778,665	Jan 02 05:00 PM
Bagai Shaun	Chief Executive Officer	Dec 18 '25	Buy	0.90	5,000	4,506	340,040	Dec 22 07:00 AM
Bagai Shaun	Chief Executive Officer	Dec 17 '25	Buy	0.85	5,000	4,262	335,040	Dec 19 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 16 '25	Buy	0.85	12,000	10,200	778,460	Dec 17 07:00 AM
Agah Ramtin	Chief Medical Officer	Dec 05 '25	Buy	0.96	10,000	9,600	766,460	Dec 08 07:00 AM
Agah Ramtin	Chief Medical Officer	Nov 24 '25	Buy	0.80	12,000	9,600	756,460	Nov 24 06:00 PM
Agah Ramtin	Chief Medical Officer	Nov 21 '25	Buy	0.80	10,000	8,000	744,460	Nov 24 06:00 PM
Bagai Shaun	Chief Executive Officer	Aug 22 '25	Buy	0.95	5,000	4,748	325,040	Aug 26 06:10 AM
Bagai Shaun	Chief Executive Officer	Aug 25 '25	Buy	0.91	5,000	4,549	330,040	Aug 26 06:10 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNXT

RenovoRx Inc

Upgrade your Finviz experience